D W Moskowitz

Summary

Affiliation: Chairman and Chief Medical Officer
Country: USA

Publications

  1. ncbi From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example
    David W Moskowitz
    Chairman and Chief Medical Officer, GenoMed, Inc, St Louis, Missouri, USA
    Diabetes Technol Ther 4:519-32. 2002
  2. ncbi Is angiotensin I-converting enzyme a "master" disease gene?
    David W Moskowitz
    GenoMed, Inc, St Louis, Missouri 63110, USA
    Diabetes Technol Ther 4:683-711. 2002
  3. ncbi Is "somatic" angiotensin I-converting enzyme a mechanosensor?
    David W Moskowitz
    GenoMed, Inc, St Louis, Missouri 63110, USA
    Diabetes Technol Ther 4:841-58. 2002
  4. ncbi Pathophysiologic implications of angiotensin I-converting enzyme as a mechanosensor: diabetes
    D W Moskowitz
    GenoMed, Inc, St Louis, Missouri 63110, USA
    Diabetes Technol Ther 5:189-99. 2003
  5. ncbi The central role of angiotensin I-converting enzyme in vertebrate pathophysiology
    David W Moskowitz
    GenoMed, Inc, 909 S Taylor, Ave, St Louis, MO 63110, USA
    Curr Top Med Chem 4:1433-54. 2004
  6. ncbi Acute oxygen-sensing mechanisms
    David W Moskowitz
    N Engl J Med 354:975-7; author reply 975-7. 2006
  7. ncbi The prevention of pain from sickle cell disease by trandolapril
    R Michael Williams
    Stanislaus Cancer Treatment Research Foundation, Modesto, CA, USA
    J Natl Med Assoc 99:276-8. 2007

Collaborators

  • R Michael Williams

Detail Information

Publications7

  1. ncbi From pharmacogenomics to improved patient outcomes: angiotensin I-converting enzyme as an example
    David W Moskowitz
    Chairman and Chief Medical Officer, GenoMed, Inc, St Louis, Missouri, USA
    Diabetes Technol Ther 4:519-32. 2002
    ..This experience suggests the power of pharmacogenomics to improve clinical outcomes for common diseases safely, quickly, and inexpensively, if effective drugs already exist...
  2. ncbi Is angiotensin I-converting enzyme a "master" disease gene?
    David W Moskowitz
    GenoMed, Inc, St Louis, Missouri 63110, USA
    Diabetes Technol Ther 4:683-711. 2002
    ....
  3. ncbi Is "somatic" angiotensin I-converting enzyme a mechanosensor?
    David W Moskowitz
    GenoMed, Inc, St Louis, Missouri 63110, USA
    Diabetes Technol Ther 4:841-58. 2002
    ..The C-terminal domain is constitutively activated by chloride. This model explains the clinical superiority of hydrophobic ACE inhibitors relative to hydrophilic ones...
  4. ncbi Pathophysiologic implications of angiotensin I-converting enzyme as a mechanosensor: diabetes
    D W Moskowitz
    GenoMed, Inc, St Louis, Missouri 63110, USA
    Diabetes Technol Ther 5:189-99. 2003
    ..In this paper we will explore how useful this hypothesis is in explaining the molecular pathogenesis of diabetes and its complications, in which aging is accelerated...
  5. ncbi The central role of angiotensin I-converting enzyme in vertebrate pathophysiology
    David W Moskowitz
    GenoMed, Inc, 909 S Taylor, Ave, St Louis, MO 63110, USA
    Curr Top Med Chem 4:1433-54. 2004
    ..sACE may auto-dimerize via a novel protein motif, the "disulfide zipper." The sACE dimer is predicted to have higher catalytic efficiency and redox resistance than tACE...
  6. ncbi Acute oxygen-sensing mechanisms
    David W Moskowitz
    N Engl J Med 354:975-7; author reply 975-7. 2006
  7. ncbi The prevention of pain from sickle cell disease by trandolapril
    R Michael Williams
    Stanislaus Cancer Treatment Research Foundation, Modesto, CA, USA
    J Natl Med Assoc 99:276-8. 2007
    ..The activation of ACE may be an early step in the arterial vaso-occlusion typical of sickle cell disease...